Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...
HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results